go therapeutics logo

GO Therapeutics

GO Therapeutics is a discovery stage start-up company developing tumor-specific antibodies for cancer immunotherapies using cancer glycoproteome. GO currently has four candidates in pre-clinical studies, each of which includes a bi-specific mechanism that targets T-cells.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://gotherapeutics.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
One Broadway,MA,2142
Cambridge
United States
Email
Contact Number
+1 617-816-4637

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/go-therapeutics” connections=”true” suffix=””]

GO Therapeutics has developed a scientific platform to identify sites of O-linked glycosylation on tumor-associated proteins and use the accessibility of these O-glycans at the plasma membrane to develop novel _hybridÓ epitopes that are part protein and O-glycan structure. These hybrid epitopes are exquisite targets for immunotherapeutics and designing antibodies hybrid antigens, by combining a tumors up-regulated protein expression with a proteins aberrant glycosylation pattern, to dramatically increase tumor specificity.

In Sep 2017, Salubris Pharmaceutical Limited has made a $5M equity investment in GO Therapeutics.